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showed a trend towards a lower risk of adenomas com-
pared to women without anti-estrogen therapy (3.7 vs. 
17.2%, p = 0.053, OR 0.16, 95% CI 0.0–1.1).  Conclusions: 
Women with breast cancer above the age of 65 years 
have an increased risk of colorectal adenomas compared 
to women without breast cancer. Women with a diagno-
sis of breast cancer should especially be encouraged 
to participate in colorectal cancer-screening programs 
which, in most countries, call for screening of all aver-
age-risk individuals over the age of 50 years. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Epidemiological studies suggest an association be-
tween the incidence of breast cancer and the incidence of 
colorectal cancer  [1–3] . Relatives of patients with breast 
cancer have been shown to develop colorectal tumors 
more frequently than controls  [4] ; conversely, families 
with a high risk of colonic cancer have breast cancers 
more frequently than controls  [5] . Furthermore, fi rst-de-
gree relatives of patients with primary carcinomas of the 
breast or of the colon more frequently develop breast can-
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 Abstract 
 Background: The frequency of colorectal adenomas and 
carcinomas was investigated in a large cohort of women 
with breast cancer in comparison with matched controls, 
since data on the occurrence of second tumors in wom-
en with breast cancer is controversial.  Design: In a cohort 
study, 188 consecutive women (median age 57 years) 
with primary breast cancer and 376 age-matched women 
who served as controls were examined by total colonos-
copy. Breast cancer patients and controls were com-
pared for the frequency of colorectal adenomas and car-
cinomas.  Results: Women with breast cancer showed a 
higher risk of colorectal adenomas than controls (14.9 
vs. 9.3%, p = 0.047, OR 1.7, 95% CI 1.0–2.9). This increased 
prevalence resulted primarily from an increased preva-
lence in the age group 65–85 (31 vs. 10%, p = 0.004, OR 
3.8, 95% CI 1.6–9.3). Colorectal carcinomas were found 
infrequently in both groups (2 in each group). Women 
with breast cancer receiving anti-estrogen therapy 
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cer or colon cancer than controls  [6] , altogether suggesting 
a common susceptibility for colorectal and breast can-
cer. 
 Cross-sectional cohort studies for the risk of colorectal 
carcinomas in women with breast cancer would need very 
large numbers of patients due to the low incidence of 
colorectal cancer. On the other hand, using adenomas as 
an endpoint limits the predictive power of such a study 
due to the fact that most individuals with adenomas will 
not develop colorectal cancer in their lifetime. Neverthe-
less, colorectal adenomas are precursors of colorectal can-
cer and are much more frequent and hence, offer a better 
approach to address the question whether women with 
breast cancer bear a higher risk of colorectal tumors. How-
ever, studies on this matter have so far revealed confl icting 
data  [7–16] and found odds ratios for the risk of subse-
quent colorectal adenomas as low as 0.7 or as high as 3.0 
 [9, 11–16] . This wide range might be explained by age dif-
ferences, small numbers of patients studied, and the fact 
that mostly only the rectum and the sigmoid colon were 
studied. This prompted us to conduct a cross-sectional co-
hort study on the frequency of colorectal adenomas or car-
cinomas by performing total colonoscopy in women with 
breast cancer, and to compare it with the frequency of 
colorectal adenomas in age-matched controls. 
 Patients and Methods 
 Patients with a recent history of breast cancer were included in 
the study group. The study patients consisted of all those attending 
the Department of Gynecology of the University Hospital Munich-
Grosshadern for follow-up after breast cancer therapy over a 24-
month period. For each study patient, 2 age-matched controls ( 8 
2 years) were recruited from women undergoing colonoscopy at the 
Department of Medicine II of the University Hospital Munich-
Grosshadern during the same time period. The indications for colo-
noscopy in the control group are summarized in  table 1 . 
 Colonoscopy was offered to all consecutive patients in the study 
and control groups during the 2-year study period. In both groups, 
medical and family histories were obtained, and data on height and 
weight were collected. The exclusion criteria are summarized in 
 table 2 . Those women who gave their informed consent were then 
submitted to total colonoscopy. The study complied with the Hel-
sinki declarations. The protocol was approved by the ethical com-
mittee of the University of Munich. Written informed consent was 
obtained from all patients studied. 
 Colonoscopy 
 In both study groups, the colonoscopies were performed by the 
same group of experienced endoscopists at the Department of Med-
icine II of the University Hospital Munich-Grosshadern. Any pol-
yps or tumors were biopsied if smaller than 5 mm, or removed 
endoscopically or surgically if larger than 5 mm. 
 Adenomas and carcinomas were classifi ed histologically as tu-
bular, tubulo-villous or villous, in accordance with the criteria of 
the WHO  [17] . 
 Statistics 
 Breast cancer patients and controls were compared for the fre-
quency of colorectal adenomas and carcinomas using the   2  test or 
the Student’s t test. Women with breast cancer who had received 
the necessary therapies were compared for the frequency of colorec-
tal adenomas using the two-sided Fisher’s exact test. p values of 
 ! 0.05 were regarded as signifi cant. Values are given as mean  8 SD 
or as median and range. 
 Results 
 Patients 
 Of 346 consecutive women with breast cancer who 
were evaluated for participation in this study, 158 were 
excluded. The reasons for exclusion were: previous 
colorectal adenomas (n = 9); previous colorectal carcino-
 Table 1. Indications for colonoscopy in the control group 
n
Occult or overt blood in the stools
(but not acute intestinal bleeding)
  55
Abdominal pain of unknown origin 122
Diarrhea   51
Constipation   46
Suspected neoplasia   53
Abdominal mass   49
 
 Table 2. Exclusion criteria in the study (n = 158) and the control 




Previous colorectal adenoma or carcinoma 24 154
Second primary carcinomas other than breast
cancer
  
  7 496
Chronic infl ammatory bowel disease   0 165
Family history
(one or more fi rst-degree relatives)
 of breast cancer or colorectal cancer   3     8
Partial or total colectomy   1 159
Previous colonoscopy within the last 5 years 49   78
Reluctance to participate 59     0
Incomplete colonoscopy   9   97
No appropriate age-match   6 205
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mas (n = 15); second primary carcinomas other than 
breast (n = 7); a family history of breast or colorectal can-
cer (n = 3); partial colectomy (n = 1); previous colonos-
copy within the last 5 years (n = 49); reluctance to par-
ticipate (n = 59), and incomplete colonoscopy (n = 9). Six 
women were not included in the evaluation because no 
appropriate age-matched controls were available. Thus a 
total of 188 women with breast cancer were studied. 
 1,738 consecutive women undergoing colonoscopy 
during the same period were evaluated for matching with 
the breast cancer patients. Excluded were: 554 women 
with previous or current malignant disease; 96 with pre-
vious colorectal adenomas; 165 with chronic infl amma-
tory bowel disease; 159 with prior partial colectomy; 8 
with a family history of breast or colorectal cancer, and 
97 women because of incomplete colonoscopy. 78 women 
were excluded because of a previous colonoscopy within 
the last 5 years. 205 women were not included in the 
evaluation because no appropriate age-matched partner 
could be found. Hence, 2 each of the appropriate 376 
control women were age-matched to each study patient. 
 The patients’ characteristics are described in  table 3 . 
The mean age of the patients was 56.6  8 12.2 years for 
the study group, and 56.9  8 12.9 years for the control 
group (p = 0.79). The mean body mass index (calculated 
as weight in kilograms divided by the square of the height 
in meters) was similar in both groups: 25.0  8 4.3 in the 
study group and 24.6  8 4.6 in the control group (p = 
0.35). 
 Frequency of Colorectal Adenomas and Carcinomas 
 Women with breast cancer had a signifi cantly higher 
incidence of colorectal adenomas than the control pa-
tients (n = 28 (14.9%) vs. n = 35 (9.3%), OR 1.7, 95% CI 
1.0–2.9, p = 0.047;  table 4 ). The age-related prevalence 
of adenomas in patients and controls showed a signifi cant 
difference between the combined age groups of 66–85: 31 
vs. 10%, p = 0.004, OR 3.8, 95% CI 1.6–9.3 ( table 5 ). 
Colorectal carcinomas were found in only 2 women with 
breast cancer and in 2 of the controls (OR 2.0, 95% CI 
0.3–14.4, p = 0.60;  table 4 ). Women with breast cancer 
had a signifi cantly higher incidence of colorectal tumors 
 Table 3. Demographic and clinical characteristics of women with 





Age, years (mean 8 SD) 56.6812.2 56.9812.9
Age range, years 34–84 32–84
White Caucasian, % 100 100
Body mass index (mean 8 SD) 25.084.3 24.684.6 
Smokers 24 (13%) 41 (11%)
Parity
0 34 (18%) 94 (25%)
1–2  113 (60%) 214 (57%)
>2 41 (22%) 68 (18%)
Menstrual status
Regular/irregular cycle 20 (11%) 55 (15%)
Perimenopausal 57 (30%) 140 (37%)
Postmenopausal  111 (59%)* 181 (48%)*
* p < 0.02.
 
 Table 4. Endoscopic results in women with breast cancer and con-
trols 




No adenoma or cancer 158 (84.0%) 339 (90.2%)
Tubular adenoma <1 cm 12 (6.4%) 20 (5.3%)
Tubular adenoma >1 cm 7 (3.7%) 3 (0.8%)
Tubulo-villous adenoma 9 (4.8%) 12 (3.2%)
High-grade dysplasia or cancer 2 (1.1%) 2 (0.5%) 
Total adenoma 28 (14.9%)** 35 (9.3%)**
Total neoplasia 30 (16.0%)* 37 (9.8%)*
* p < 0.04; ** p < 0.05.
 
 Table 5. Age-related prevalence of adenomas in women with breast 
cancer and in controls 
Age 
years
Patients with adenomas 
in the study group
Patients with adenomas 
in the control group
n % n %
<36 0/2 0.0 0/2 0.0
36–45 0/20 0.0 5/75 6.7
46–55 9/77 11.7 13/136 9.6
56–65 4/40 10.0 7/67 10.4
66–75 11/39 28.2* 4/54 8.9*
76–85 4/10 40.0* 6/42 14.3*
Total 28/188 14.9 35/376 9.3
Between the combined age groups 66–85 a signifi cant difference 
was observed (*): OR 3.79 (95% CI 1.43–10.20) and RR 2.94 (95% 
CI 1.43–6.05).
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(carcinomas and adenomas) than control patients (n = 30 
(16.0%) vs. n = 37 (9.8%), OR 1.7, 95% CI 1.0–2.9, p = 
0.039;  table 4 ). 
 No statistically signifi cant difference was noted be-
tween the study group and the control group with regard 
to the site of adenomas. In the study group 6 women had 
adenomas in the right colon and 22 women in the left co-
lon, whereas in the control group 2 women had adenomas 
in the right colon and 33 women in the left colon. The 2 
carcinomas in each group were found in the rectum, and 
sigmoid in the study group and in the right colon and rec-
tum in the control group, respectively. 
 There was no difference between the 2 groups in terms 
of the histological grading of the adenomas: of the adeno-
mas found in the women with breast cancer 68% were 
tubular and 32% were tubulo-villous, while of those found 
in the control group 66% were tubular and 34% were tu-
bulo-villous ( table 4 ). 
 Time Interval, Adjuvant Therapy, Menstrual Status, 
Tumor Site, and Histological Grading 
 The interval between the diagnosis of breast cancer 
and colonoscopy was 3.5  8 3.3 years for all women with 
breast cancer, and 4.9  8 4.1 years for those with breast 
cancer and colorectal adenomas (n.s.). 
 In women with breast cancer receiving anti-estrogen 
therapy (n = 31) only 1 adenoma was observed as com-
pared to women who received no anti-estrogen therapy 
(n = 157) in whom 27 adenomas were detected. However, 
this trend failed to be signifi cant (3.2 vs. 17.2%, p = 0.053, 
OR 0.16, 95% CI 0.0–1.1;  table 6 ). Subsequent analysis 
of hormone receptor status revealed no difference be-
tween both groups. However, more women in the breast 
cancer group than in the control group were post-meno-
pausal (59 vs. 48%, p  ! 0.02;  table 3 ). 
 Prevalence of Adenomas with Regard to Indications 
for Colonoscopy 
 The prevalence of adenomas in the control group was 
analyzed with regard to the six indications for colonos-
copy: most adenomas in the control group were found in 
patients with constipation (15.2%), followed by patients 
with abdominal pain (9.8%), occult or overt blood (9.1%), 
abdominal mass (8.1%), suspected neoplasia (7.6%), and 
diarrhea (5.9%). The two carcinomas in the control group 
were associated with the indication abdominal mass. 
 Discussion 
 In this cross-sectional study, women with primary 
breast cancer showed a higher risk of colorectal adenomas 
than matched controls with an OR of 1.7. The increased 
prevalence of adenomas in the breast cancer patients does 
primarily result from a signifi cantly increased prevalence 
in the age group 65–85, in which 31% of the breast cancer 
patients have adenomas as compared to only 10% of the 
control group. Therefore, due to this observation and the 
fact that the time interval from breast cancer diagnosis to 
colonoscopy was similar in both groups, one could as-
sume that the adenoma risk is predominantly increased 
in women with breast cancer who are older than 65 
years. 
 So far, comparable cohort studies revealed confl icting 
data on this matter  [9–16] . Studies with the result of an 
elevated risk did either not reach signifi cance  [13] or eval-
uated only the rectum and sigmoid colon  [13–16] . In a 
study by Bremond et al.  [14] , a group of 145 women with 
breast cancer had a 2.5-fold higher incidence of colorectal 
adenomas than a control group (n = 144), when only the 
rectum and sigmoid were studied. Rozen et al.  [15], and 
Jouin et al.  [16] , found colorectal adenomas to be 2.7–3.0 
times more common in women with breast cancer than 
in controls. However, in most of their patients only a sig-
moidoscopy was performed. On the basis of the increas-
ing numbers of colorectal neoplasms found in the right 
colon in women  [18] , and the fact that women have a 
 Table 6. Adjuvant therapy in women with breast cancer, and prev-






No adjuvant therapy 57 7 12.3
Radiation 51 8 15.7
Chemotherapy + anti-estrogen 2 0 0.0*
Anti-estrogen + radiation 25 1 4.0*
Chemotherapy + radiation 49 12 24.5
Chemotherapy + radiation + anti-estrogen 4 0 0.0*
Total 188 28 14.8
No signifi cant differences in terms of colorectal adenoma rates 
were observed between each group in comparison to the group with-
out therapy. However, in women receiving anti-estrogen therapy 
(n = 31) only 1 woman had an adenoma, as compared to women 
receiving no anti-estrogen therapy (n = 157) of whom 27 had adeno-
mas: * p = 0.053.
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higher incidence of right-sided colonic cancer than men 
 [19] , a complete colonoscopy as performed in our trial 
might be warranted. In one study, Murray et al.  [12] , were 
unable to fi nd any increased adenoma rate (OR 0.7) in 
breast cancer patients, which, however, might be ex-
plained by the relatively small number (n = 43) of patients 
with breast cancer examined. These 5 studies  [12–16] 
were summarized in a meta-analysis  [9] , revealing an in-
creased risk of 1.7 for colorectal adenomas in women with 
breast cancer, a value similar to that observed in our 
study. 
 A more recent study analyzed the incidence of colorec-
tal polyps in patients with a history of breast cancer in 
Taiwan  [20] . The authors found colorectal adenomas and 
one carcinoma in 10 of 89 women. However, no control 
group was used. 
 The studies of Rozen et al.  [15] and Rex et al.  [11] 
analyzed population-based control groups, which are con-
sidered the most appropriate approach to the selection of 
a control group  [9] . However, the volunteer group in the 
fi rst study  [15] was 5 years younger than the breast cancer 
group and, therefore, a bias due to the age dependence of 
colorectal tumors cannot be excluded. On the other hand, 
in the study of Rex et al.  [11] , the volunteer group was 5 
years older than the breast cancer group. These points 
might explain why Rozen et al.  [15] found a higher risk 
and Rex et al.  [11] found a lower risk than in our study. 
Acquiring several hundreds of asymptomatic control pa-
tients for colonoscopy studies is diffi cult. Therefore, as in 
most other studies, we used in- and out-patients referred 
for colonoscopy. However, rather than using controls pre-
senting with symptoms, it might have been better to have 
selected asymptomatic individuals presenting for colo-
noscopy screening, which is now widespread in Germany 
but was not when the study was initiated. However, it is 
also likely that small adenomas did not cause the symp-
toms. In order to exclude the bias of age, our study pa-
tients were age-matched with 2 control patients. 
 In our control group 40% of the women were examined 
for suspected neoplasia, abdominal mass, or occult or 
overt blood in the stools, indications with a high likeli-
hood for colorectal neoplasias. Taking this fact into ac-
count, our calculated OR for the adenoma risk might 
rather be underestimated than overestimated. In this 
study, almost one third of the controls were excluded be-
cause of a prior malignant disease and of prior adenomas. 
Inclusion of these groups could have changed the fi ndings 
signifi cantly. On the other hand, the inclusion of patients 
with adenomas or malignomas as controls seemed even 
less appropriate. 
 Our study was not designed to establish the incidence 
of colorectal carcinomas in breast cancer patients since 
the number of expected cancer cases would be too small 
to show signifi cant differences. 
 In a recently published paper, Newschaffer et al.  [21] 
used the Surveillance Epidemiology and End Results 
(SEER) database to estimate the risk of colorectal cancer 
after a diagnosis of breast cancer in more than 200,000 
women. Surprisingly they found that women with previ-
ous breast cancer were 5% less likely to develop colon 
cancer and 13% less likely to develop rectal cancer than 
women in a general population. The authors speculate 
that more vigilant screening in breast cancer patients 
might have lead to increased endoscopic removal of 
colorectal polyps and thus to less cancer development. 
 Although we did not intend to analyze differences in 
the respective breast cancer therapy groups we, interest-
ingly, observed that women with breast cancer who re-
ceived anti-estrogen therapy showed a trend towards a 
lower risk of adenomas than women who received no 
anti-estrogen therapy ( table 6 ). The infl uence of anti-es-
trogen therapy on adenoma growth is a matter of specula-
tion, but our data are consistent with recent observations 
 [22] : anti-estrogen drugs prevent the development of can-
cer in patients who are at high risk of developing second 
primary tumors after surgical removal of the initial tu-
mor. On the other hand, meta-analyses summing up stud-
ies on women with breast cancer who received tamoxifen 
showed that this drug had no apparent effect on the inci-
dence of colorectal cancer  [23, 24] . In addition, it is dif-
fi cult to evaluate the effects of anti-estrogens in our study, 
if these patients received anti-estrogens with or without 
chemotherapy and radiation. Larger cross-sectional stud-
ies examining the chemopreventive effect of anti-estro-
gen drugs could possibly clarify their role in the preven-
tion of colorectal adenoma growth. 
 Interestingly, more post-menopausal women were 
among the breast cancer patients than among controls. A 
recent paper showed that the menopausal status is con-
sidered a confounding risk factor (OR 1.5) for the devel-
opment of colorectal cancer  [25] . However, in that study 
the elevated cancer risk was only true for women who 
have never used hormone replacement therapy. We think 
that in our study the infl uence of the menopausal status 
is of only minor importance, since 43% of our breast can-
cer patients were treated with hormone replacement ther-
apy and/or chemotherapy. Furthermore the most signifi -
cant fi nding in our study, the difference between the ad-
enoma rates in the age groups 65–85, was observed among 
women who were all post-menopausal. 
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 A potential limitation of our analysis is that we have 
not analyzed genetic markers, like BRCA1, which could 
link breast with colorectal cancer  [26] . However, other 
studies have not shown an increased colorectal cancer risk 
in  BRCA mutation carriers  [27, 28] . In addition, we ex-
cluded patients with a family history of one or more fi rst-
degree relatives with breast cancer or colorectal cancer. 
Other common pathogenetic factors that could explain 
differences, like obesity  [29] or age, are unlikely as well, 
since both populations showed no differences with re-
spect to age and body mass index ( table 3 ). 
 In summary, our data suggest that women with breast 
cancer have about twice the risk of developing colorectal 
adenomas than women without breast cancer. This risk 
mainly seems to exist in those women with breast cancer 
who are older than 65 years. As a consequence of these 
observations, women with a diagnosis of breast cancer 
should especially be encouraged to participate in colorec-
tal cancer screening programs, which, in most countries, 
call for screening of all average-risk individuals over the 
age of 50 years  [30] . 
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